Amarin Corporation plc · NASDAQ:AMRN

Amarin — Investor Presentation (January 2011)

32 slides from Amarin's investor presentation, January 2011

  1. Slide 1: Next Generation Lipid Modification in Cardiovascular Disease

    TM Next Generation Lipid Modification in Cardiovascular Disease Investor Presentation Nasdaq: AMRN www.amarincorp.com 1 January 2011

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation contains forward-looking statements, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future eve

  3. Slide 3: Overview of Lead Product - AMR101

    Overview of Lead Product - AMR101  Best-in-class positioning potential for treating very high triglycerides (>500 mg/dL) ● Primary endpoint met for pivotal MARINE trial as reported November 29, 2010 ● Data suggests dosing flexibility and no increase in LDL-C providing significant market differentia

  4. Slide 4: Emerging Clinical Focus on Lowering Triglycerides with Omega-3

    Emerging Clinical Focus on Lowering Triglycerides with Omega-3 TRADITIONAL EMERGING TREATMENT FUTURE POTENTIAL WITH PHYSICIAN FOCUS + PRACTICE NO LDL INCREASE LDL-C & Total Cholesterol Triglycerides Triglycerides Lipid Parameters LDL HDL TGs LDL TGs Key Treatments Statins, Niacin, Fibrates Amarin’s

  5. Slide 5: Large Underpenetrated Market Opportunities

    Large Underpenetrated Market Opportunities 150 million 70 % of People in U.S. >20 Yrs. Old 60 Only 3.6% treated with Rx 50 meds 40 Future Potential Potential AMR101 indications 67% 30 34 million 36 million Lovaza indication 20 10 15% 16% 3.8 million ~2% 0 0-149 mg/dL 150-199 mg/dL 200-499mg/dL 500-2

  6. Slide 6: The Product: AMR101

    The Product: AMR101 6 January 2011

  7. Slide 7: Clear Differentiation between AMR101 and Lovaza

    Clear Differentiation between AMR101 and Lovaza Lovaza AMR101 a highly purified mixture ethyl icosapentate – of fatty acids single active ingredient Ethyl EPA (465 mg) Ethyl-EPA Ethyl DHA (>960 (375 mg) mg) Additional omega 6, 7 & 9 (100mg) Other omega-3 acid ethyl esters (60mg) fatty acids ~30 mg D

  8. Slide 8: AMR101: Ethyl icosapentate (E-EPA) - a single active moiety

    AMR101: Ethyl icosapentate (E-EPA) - a single active moiety positioned to provide best overall triglyceride management  Comparison of semi-synthetic AMR101 with E-EPA other Omega-3 containing preparations AMR101  Prescription Omega-3 are clearly differentiated from fish oil (impurities removed, co

  9. Slide 9: AMR101 Targets Multiple Clinical Needs

    AMR101 Targets Multiple Clinical Needs Potential Follow-on indications: Prevention of cardiovascular events; combination with statins; inflammation Population: Patients with cardiovascular risk factors Omega-3 competition: None approved in U.S. Second indication: Reducing hypertriglyceridemia in pat

  10. Slide 10: Clinical Data: MARINE Trial

    CLINICAL DATA: MARINE TRIAL 10 January 2011

  11. Slide 11: MARINE Trial Overview: Primary Endpoint Met

    MARINE Trial Overview: Primary Endpoint Met 6-8 week 12-week double blind, screening 80 patients per arm 2 g/day Top-line results 4 g/day reported November 29, 2010 - Primary end-point achieved at Placebo both 2g and 4 g doses Safety & efficacy 4 weeks 11 12 assessed ■ 229 patients with very high tr

  12. Slide 12: MARINE Study Population

    MARINE Study Population • 25% of patients were on background statin therapy ● MARINE is the first trial of patients with TGs >500mg/dL to study a triglyceride lowering therapy on top of statin ● Concomitant statins evenly distributed across dose groups • Baseline Triglycerides (TGs) ● 2 gram dosing

  13. Slide 13: MARINE Study Results – Lipid Results; Median Changes

    MARINE Study Results – Lipid Results; Median Changes • 4 grams of AMR101 as compared to placebo ● Reduced TGs by 33% (p<0.0001); 45% in patients with TG>750 mg/dl (p=0.0001) ● Reduced non-HDL-C by 18% (p<0.001) ● Reduced LDL-C by a non-significant 2.3%* • 2 grams of AMR101 as compared to placebo ● R

  14. Slide 14: MARINE Study Results: Additional Data

    MARINE Study Results: Additional Data • Reduction in achieved pre-specified biomarker endpoints (p<0.05 for all and p<0.01 for some) ● Apo-B ● Lp-PLA2 ● VLDL-C ● Total Cholesterol • AMR101 Safety ● Well tolerated ● Robust safety profile compares favorably to other triglyceride lowering therapies ● N

  15. Slide 15: MARINE Trial Results Exceeded Our Expectations

    MARINE Trial Results Exceeded Our Expectations Pre-Data Post-Data Triglycerides Significant reduction Same LDL-C increase Half the increase of existing No LDL-C increase Total cholesterol and Similar to existing class Significant reductions non-HDL-C Inflammation Limited focus Potential additional i

  16. Slide 16: ANCHOR Trial

    ANCHOR TRIAL 16 January 2011

  17. Slide 17: ANCHOR Trial Results Expected Q2 2011

    ANCHOR Trial Results Expected Q2 2011 ANCHOR TRIAL Size: 702 patients Status: Completed patient enrolment and randomization Optimism regarding TG lowering of patients to treatment arms in December 2010 efficacy and no LDL effect in statin Population: Patients with mixed dyslipidemia (high patients d

  18. Slide 18: Outcomes Data (from use in Japan)

    Outcomes Data (from use in Japan) 18 January 2011

  19. Slide 19: JELIS Results Overview: Ethyl-EPA decreases coronary events

    JELIS Results Overview: Ethyl-EPA decreases coronary events  The only study of which we are aware to show incremental benefit to statins  CV outcomes study showed benefit in low risk patients  Enhanced benefit in high risk subgroups ● Elevated triglycerides and low HDL ● Stroke ● 2 prevention ●

  20. Slide 20: JELIS study: Ethyl-EPA reduces Coronary Events - Total Cohort

    JELIS study: Ethyl-EPA reduces Coronary Events- Total Cohort 18,645 Japanese men and women randomized to statin alone or statin + Ethyl- EPA (Epadel) and followed for 5 years 4 Control (statin) Cumulative Incidence of Major EPA (statin+Epadel) –19% (p=0.011) Coronary Events (%) 3 2 1 0 0 1 2 3 4 5 Y

  21. Slide 21: JELIS study: E-EPA reduces Coronary Events - Sub Group

    JELIS study: E-EPA reduces Coronary Events- Sub Group TG>150mg/dl and HDL <40mg/dl Saito et al, 2008 Atherosclerosis 21 January 2011

  22. Slide 22: The Company and Financials

    The Company and Financials 22 January 2011

  23. Slide 23: Experienced Management Team

    Experienced Management Team Experience (years) Joseph Zakrzewski – CEO & Chairman •Former COO of Reliant Pharmaceuticals (which launched Lovaza and was sold to >20 GSK for $1.6B) and former VP Corporate Business Development Eli Lilly John Thero – President >25 •Former senior roles for multiple emerg

  24. Slide 24: AMR101: Commercialization Strategy

    AMR101: Commercialization Strategy Partnering ● Preferred for commercialization ● Multiple partner discussions ongoing ● Markets outside U.S. to be prioritized by partner Additional trials to be funded by partner ● Multiple expanded label opportunities Supplier ● Initial supply from Japan ● Same

  25. Slide 25: AMR101: Intellectual Property Position

    AMR101: Intellectual Property Position Upside: 2030 Multiple filed applications • Indications - Many applications filed based on MARINE results - Additional applications anticipated based on ANCHOR results • Composition – Highly Stable EPA Base: 2021 Highly Purified Ethyl EPA AMR101 composition 

  26. Slide 26: Capitalization Summary

    Capitalization Summary Cash (9/30/2010) $31.4M Debt None Common stock and equivalent shares (9/30/2010) : Common shares 101.3M Options 12.3M (average exercise price of $2.47) Warrants 38.7M (average exercise price of $1.77) Total if all exercised 152.3M Top shareholders*: % Abingworth 17.0 Sofinnova

  27. Slide 27: Milestone Summary: History of Positive Achievement

    Milestone Summary: History of Positive Achievement Guidance Expressed Most Recent At Start of 2010 Guidance Begin patient enrolment: MARINE Early 2010 Done on schedule ANCHOR Early 2010 Done on schedule Complete patient enrolment: MARINE 2011 Done mid-2010 ANCHOR 2011 Done late-2010 Top-line results

  28. Slide 28: Overview of Lead Product - AMR101

    Overview of Lead Product - AMR101  Best-in-class positioning potential for treating very high triglycerides (>500 mg/dL) ● Primary endpoint met for pivotal MARINE trial as reported November 29, 2010 ● Data suggests dosing flexibility and no increase in LDL-C providing significant market differentia

  29. Slide 29: Appendix

    APPENDIX 29 January 2011

  30. Slide 30: Lovaza/Omacor Clinical Study Summary for Patients with TG >500 mg/dL

    Lovaza/Omacor Clinical Study Summary for Patients with TG >500 mg/dL LDL-C References Treatment Dose Duration Baseline TG TG Percent N Percent (all >10 yrs old) (g/day) (wk) (mg/dL) Change Change Harris 1997 Lovaza 42 4 16 926 -45 +31 McKeone 1997 Lovaza 40 4 6 500-2000 -26 no data Abe 1998 Lovaza 2

  31. Slide 31: Multiple Studies Demonstrate that DHA elevates LDL-C

    Multiple Studies Demonstrate that DHA elevates LDL-C Study DHA Treatment Baseline Change in Baseline Change in LDL- author and treatment duration TG TG LDL –C C year mg/dl “-”= decrease Kelley 3g 90 days 225 -24.4% 120 +13.5% 2007 Maki 1.5g 6 weeks 179 -21.4% 142 +12.0% 2005 Theobald 1.5g 3 months 1

  32. Slide 32: Multiple Studies Demonstrate that EPA is LDL Neutral

    Multiple Studies Demonstrate that EPA is LDL Neutral Study author and EPA Treatment Baseline Change in Baseline Change in LDL- year treatment duration TG TG LDL –C C mg/dl “-”= decrease Kurabayashi 2000 1.8g 48 weeks 136 -14% 165 0% Yamashita 1995 1.8g 8 weeks 161 -25% 139.5 -4.7% No Ando 1999 1.8g

Amarin — Investor Presentation (January 2011) on 6ix